Illumina, Inc. · Healthcare
The price already needs more growth than analysts forecast, at both a 9% and an 8% discount rate.
At a 17.0% margin the price requires 19.8% 3y revenue CAGR against 7.4% consensus, a cushion of -24.8pt versus a 1pt correction cut. Price needs more growth than consensus at any nearby discount rate, so the correction has room to go further. Price paid for acceleration consensus doesn't show; small funding channel.
Would recover if: China and funding pressure keep growth well below the 15.8% the price needed. We re-check this against analyst estimates every evening.
10 years, at a 17% margin analysts expect
+5.4%/yr over 10 years once faded to terminal growth
points off 3-year analyst growth
12 published targets, set before the drop
Does the profit analysts build their margin on actually arrive as cash? Measured over the last 3 annual statements filed before this test.
How much of reported profit arrived as operating cash. Below 0.8× is a red flag.
Profit not backed by cash, as a share of assets, latest year. Above 10% is a red flag.
Staff paid in shares instead of cash, which flatters margins. Above 10% is a red flag.
Dilution of each share's claim on the business. Above 3% a year is a red flag.
Non-operating gains in the latest year. Above 25% is a red flag.
After capex. Shown for context: heavy investment is not bad earnings, so it is never solved under.
From the priced-in reconstruction of Sep 24, 2026. Its figures use that day's price and free-cash-flow margin, so they can differ from the stress test above.
The price sits at the 92nd percentile of published models, 23% above the median target of $208, meaning the market has firmly rejected the bear cases and is already paying for a growth acceleration that most analysts have not yet endorsed.
Can Illumina's core sequencing segment actually deliver the +15.8% revenue growth the price requires, and is the available unit-volume data precise enough to confirm or deny that acceleration?
What the price refuses to pay for, and the full reconstruction, on the ILMN quote page →A stress test of whether this narrative is still paid for by analyst forecasts, not a forecast that the stock will rise. The price-implied growth on its own has not predicted returns in our testing, and this list (sealed Nov 21, 2026) has not been graded yet. Cut sizes are assumptions. Not investment advice. Back to all names